Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Drug Investment Return Down 12% Since Waxman/Hatch - CBO Report

Executive Summary

The commercial return from marketing a new drug has declined by 12% since the Waxman/Hatch Act was enacted in 1984, the Congressional Budget Office estimates in a July report.

You may also be interested in...

Biosimilars Pathway Seen As Part Of Health Care Reform Debate Next Year

The potential for cost savings from biosimilars is likely to entangle the debate over a pathway for their approval into the discussion on health care reform that will unfold in the next Congress

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts